NY Times reporter Amy Harmon has a gripping three-part article appearing in print this week about a new melanoma drug, PLX4032. While new drugs are featured in the media everyday, this one definitely stands out from the rest. Results from early clinical trials are beyond impressive and worth reading about, especially if you or someone you know suffers from melanoma. The article follows patients participating in the clinical trials for PLX4032, as well as the doctors researching the drug. The article gives a unique glimpse into the world of clinical trials with "behind the scenes" access. Check out Part 1, Part 2, and Part 3 of Amy Harmon's NY Times article about PLX4032.
Explore Cancer
Must Reads
Most Popular
Glad to see your post on this series. From our perspective, the melanoma community isn’t waiting for a “miracle” to fall out of the sky to help patients. It’s clear that no single drug will likely effectively treat the disease; instead, a combination of drugs may be the answer. The Melanoma Research Foundation (MRF) is coordinating the Melanoma Breakthrough Consortium to accelerate research by bringing together leaders in drug development, laboratory and clinical research to find effective treatments. This collaboration will take years off the process. Patients with advanced melanoma have few or no treatment options and there’s no doubt in the urgency of moving forward to test new therapies today. More information is available at http://www.melanoma.org.
Tim Turnham
Executive Director
Melanoma Research Foundation